SCHEMBL23054692

SCHEMBL23054692

C#C[C@]1(CO)O[C@@H](c2ccc3c(N)nc(N)nn23)C(O)C1O

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ POLRMT O00411 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29323884 1.00 POLRMT (0.32) POLRMT
SCHEMBL29323088 1.00 POLRMT (0.32) POLRMT
SCHEMBL29323091 0.90 — —
SCHEMBL23054691 0.90 — —
SCHEMBL29323470 0.89 POLRMT (0.31) POLRMT
SCHEMBL29323092 0.84 — —
SCHEMBL23054688 0.84 — —
SCHEMBL23054687 0.83 POLRMT (0.46) POLRMT
SCHEMBL29323062 0.83 POLRMT (0.46) POLRMT
SCHEMBL29323823 0.83 POLRMT (0.46) POLRMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238323-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES EMORY UNIVERSITY 2024-07-18 — — US disclosed
US-20210060051-A1 COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS EMORY UNIVERSITY 2021-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210060051-A1 COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS NOX1, NOX3, NOX4 POLRMT 426/4885
US-20240238323-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES MTAP, PNP, SARS1 POLRMT 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback